Detail akcie Natera online

Business Summary: Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Natera Inc revenues increased 57% to $1.7B. Net loss decreased 56% to $190.4M. Revenues reflect Insurance carriers segment increase of 65% to $1.57B, United States segment increase of 58% to $1.66B, Americas, excluding U.S segment increase of 35% to $6.6M. Lower net loss reflects Interest and other income increase of 78% to $43.2M (income), Interest expense decrease of 15% to $10.7M (expense).